申请人:MERCK FROSST CANADA LTD
公开号:WO2011020193A1
公开(公告)日:2011-02-24
Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency. wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6-alkyl or C3-6-cycloalkyl, wherein said C1-6-alkyl or C3-6-cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or -(C=O)-, -CH(OH)-, -CH2- or =CH-; U is a bond or -CH2-, or for the case when V is =CH-, U is -CH=; X is =CH-, =CF-, =C(OR3)-, or -C=O-; and Y is =CH-, =CF-, =N-, or for the case when X is -C=O-, Y is -N(R3)-.
肾素抑制剂是螺环哌啶酰胺,其结构式为(I),以及其药物组合物,用于治疗心血管疾病和肾功能不全。其中n在每次出现时,独立地为0、1或2;R1为氢、C1-6-烷基或C3-6-环烷基,其中所述的C1-6-烷基或C3-6-环烷基基团可以独立地被1-3个卤素取代;A为(i)五元或六元饱和或不饱和杂环或碳环单环,或(ii)与另一个五元或六元饱和或不饱和杂环或碳环单环融合的五元或六元饱和或不饱和杂环或碳环环;V为键或-(C=O)-、-CH(OH)-、-CH2-或=CH-;U为键或-CH2-,或当V为=CH-时,U为-CH=;X为=CH-、=CF-、=C(OR3)-或-C=O-;Y为=CH-、=CF-、=N-,或当X为-C=O-时,Y为-N(R3)-。